RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.
Umesalma S, Kaemmer CA, Kohlmeyer JL, Letney B, Schab AM, Reilly JA, Sheehy RM, Hagen J, Tiwari N, Zhan F, Leidinger MR, O'Dorisio TM, Dillon J, Merrill RA, Meyerholz DK, Perl AL, Brown BJ, Braun TA, Scott AT, Ginader T, Taghiyev AF, Zamba GK, Howe JR, Strack S, Bellizzi AM, Narla G, Darbro BW, Quelle FW, Quelle DE.
Umesalma S, et al. Among authors: bellizzi am.
J Clin Invest. 2019 Mar 4;129(4):1641-1653. doi: 10.1172/JCI123049. eCollection 2019 Mar 4.
J Clin Invest. 2019.
PMID: 30721156
Free PMC article.